Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17543319 | 0.92 | MAPT (0.47) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL5952271 | 0.89 | MAPT (0.48) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL2784570 | 0.84 | MAPT (0.49) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL20226660 | 0.80 | TLR8 (0.43) | MAPTL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL7893305 | 0.79 | ALDH1A1 (0.43) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL4568234 | 0.79 | HSD17B10 (0.43) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL8599602 | 0.79 | PPOX (0.45) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL27304096 | 0.79 | NPC1 (0.46) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL19156087 | 0.77 | KDM1A (0.41) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL29953693 | 0.76 | KDM1A (0.38) | MAPTL3MBTL1ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-8362248-B2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1911756-B9 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-1911756-B1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1911756-A2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1732562-B1 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PC, GPR119, PNPO | MAPT 4243/4885L3MBTL1 3100/4885ALDH1A1 269/4885 |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | MAPT 3285/4885L3MBTL1 2840/4885ALDH1A1 4143/4885 |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PLPBP, PNPO, PDXK | MAPT 3480/4885L3MBTL1 4315/4885ALDH1A1 238/4885 |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PNPO, PLPBP, FPGS | MAPT 3761/4885L3MBTL1 2953/4885ALDH1A1 342/4885 |
| US-10711032-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | MAPT 3285/4885L3MBTL1 2840/4885ALDH1A1 4143/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | MAPT 2999/4885L3MBTL1 2855/4885ALDH1A1 4113/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | MAPT 2999/4885L3MBTL1 2855/4885ALDH1A1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.